A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02318394
• Other study ID #: D6060C00001
• Status: Completed
• Phase: Phase 1
• First received: December 3, 2014
• Last updated: January 26, 2018
• Start date: March 2, 2015
• Est. completion date: January 9, 2018

Study information

• Verified date: January 2018
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors

Description:

This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and preliminary anti-tumor activity in adult subjects with selected advanced solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: January 9, 2018
• Est. primary completion date: January 9, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Subjects must have confirmed advanced solid tumor and have progressed, are refractory, or are intolerant to standard therapy appropriate for tumor type. Subjects should not have received more than 3 prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies.

• Subjects must have at least 1 measurable lesion.

• Consent to provide archived tumor specimens

• Willingness to undergo pre-treatment and on-treatment biopsy.

• Adequate organ function.

• Use of highly effective contraception (females) or male condom plus spermicide (males).

Exclusion Criteria:

• Prior treatment with TNFRSF agonists.

• Subjects who have received certain prior immunotherapy or had toxicities relating to prior immunotherapy may not be permitted to enroll.

o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an adverse event.

• History of severe allergic reactions to any unknown allergens or any components of the study drug formulations.

• Receipt of any conventional or investigational anticancer therapy within 28 days prior to the first dose of MEDI0562.

• Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.

• Unresolved toxicities from prior anticancer therapy.

• Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.

Related Conditions & MeSH terms

• Advanced Solid Tumors

Intervention

Biological:
• MEDI0562
Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.

Locations

Country	Name	City	State
Korea, Republic of	Research Site	Seoul
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Bronx	New York
United States	Research Site	Dallas	Texas
United States	Research Site	Detroit	Michigan
United States	Research Site	Houston	Texas
United States	Research Site	Huntersville	North Carolina
United States	Research Site	La Jolla	California
United States	Research Site	Minneapolis	Minnesota
United States	Research Site	New York	New York
United States	Research Site	Pittsburgh	Pennsylvania
United States	Research Site	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)	The maximum tolerated dose/maximum administered dose will be determined by the number of participants experiencing DLTs. The safety profile will be assessed through number of participants experiencing AEs, SAEs, abnormal laboratory parameters, vital signs and electrocardiogram (ECG) results.	From time of informed consent through 12 weeks after last dose of MEDI0562
Secondary	Objective response rate (ORR)	The ORR is defined as the proportion of subjects with confirmed immune related (ir)CR or confirmed irPR	Estimated to be from time of informed consent up to 5 years
Secondary	Maximum observed concentration (Cmax), area under the curve (AUC), clearance (CL) and terminal half-life of MEDI0562	The endpoints for assessment of PK of MEDI0562 include MEDI0562 concentrations in serum at different timepoints after MEDI0562 administration.	From first dose of MEDI0562 through to 30 days after last dose of investigational product
Secondary	Number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)	The immunogenicity of MEDI0562 will be assessed by summarizing the number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)	From first dose of MEDI0562 through to 30 days after last dose of investigational product
Secondary	Induction of proliferation markers on various lymphocyte subsets, immunohistochemistry of tumor biopsies and assessment of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocyte phenotypic markers	The endpoints for assessment of pharmacodynamic activity include induction of proliferation markers in various lymphoctye subsets, immunohistochemistry of tumor biopsies and assessment of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocyte phenotypic markers	From time of informed consent through 12 weeks after last dose of investigational product
Secondary	Disease control rate (DCR)	The DCR is defined as the proportion of subjects with irCR, irPR, or irSD (subjects achieving irSD will be included in the DCR if they maintain irSD for =8 weeks)	Estimated to be from time of informed consent up to 5 years
Secondary	Duration of response (DoR)	Duration of response will be defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.	Estimated to be from time of informed consent up to 5 years
Secondary	Progression-free survival (PFS)	Progression-free survival will be measured from the start of treatment with MEDI0562 until the first documentation of confirmed immune-related disease progression or death due to any cause, whichever occurs first.	Estimated to be from time of informed consent up to 5 years
Secondary	Overall survival (OS)	Overall survival will be determined as the time from the start of treatment with MEDI0562 until death due to any cause.	Estimated to be from time of informed consent up to 5 years